Table 2.

Poor prognostic factors of pharmacokinetic origin and immune response to anti-TNFs.

Parameter	Adalimumab	Infliximab	All cohorts
θpop	−11.3 ± 2.9 (p< 0.001)	−9.1 ± 1.2 (p< 0.001)	−10.1 ± 1.2 (p< 0.001)
θcov: score =1 versus 0	+4.5 ± 2.5 (p = 0.07)	+1.8 ± 1.1 (p = 0.102)	+2.5 ± 0.9 (p = 0.006)
θcov: score =2 versus 0	+6.2 ± 2.6 (p = 0.017)	+2.6 ± 1.2 (p = 0.030)	+3.8 ± 1.1 (p< 0.001)
θtime	+0.006 ± 0.001 (p = 0.030)	+0.006 ± 0.001 (p = 0.030)	+0.006 ± 0.001 (p< 0.001)

Model, logit(Probability of CRP Based Remission) = θ_pop + θ_covi * cov_i + ···.